{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Komura K"],"funding":["Naito Foundation","the Kenzo Suzuki Memorial Foundation","Japanese Urological Association","National Cancer Center Research and Development Funds","Takeda Science Foundation","Japan Agency for Medical Research and Development","Japan Society for the Promotion of Science"],"pagination":["185"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10657138"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["<h4>Background</h4>Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA).<h4>Methods</h4>A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues from a cohort of OMPU-NCC Consortium Japan was retrospectively performed by integrating the whole-exome and RNA-sequence dataset and clinicopathological record. A median follow-up duration of all BLCA cohort was 31 months.<h4>Results</h4>FGFR3 alterations (aFGFR3), including recurrent mutations and fusions, accounted for 44% of non-muscle invasive bladder cancer (NMIBC) and 15% of muscle-invasive bladder cancer (MIBC). Within MIBC, the consensus subtypes LumP was significantly more pr"],"journal":["Molecular cancer"],"pubmed_title":["The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer."],"pmcid":["PMC10657138"],"funding_grant_id":["2020-A-2 and 2023-S-6","21H04828","21H03070","JP22jm0210085, JP22am0401007, and JP22ym0126804 (21-A-22)"],"pubmed_authors":["Tsutsumi T","Ura A","Hayashi T","Ohno T","Takahara K","Nakamori K","Taniguchi K","Tanaka T","Inamoto T","Tsujino T","Nishimura K","Tokushige S","Ishida M","Shiraishi Y","Hirosuna K","Azuma H","Yoshikawa Y","Komura K","Hirose Y","Konuma T","Yoshimi A","Takai T","Kinoshita S","Ajiro M","Ono F","Maenosono R","Yamazaki S"],"additional_accession":[]},"is_claimable":false,"name":"The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.","description":"<h4>Background</h4>Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA).<h4>Methods</h4>A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues from a cohort of OMPU-NCC Consortium Japan was retrospectively performed by integrating the whole-exome and RNA-sequence dataset and clinicopathological record. A median follow-up duration of all BLCA cohort was 31 months.<h4>Results</h4>FGFR3 alterations (aFGFR3), including recurrent mutations and fusions, accounted for 44% of non-muscle invasive bladder cancer (NMIBC) and 15% of muscle-invasive bladder cancer (MIBC). Within MIBC, the consensus subtypes LumP was significantly more pr","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-05-29T08:07:56.113Z","creation":"2025-04-06T01:23:54.989Z"},"accession":"S-EPMC10657138","cross_references":{"pubmed":["37980528"],"doi":["10.1186/s12943-023-01897-6"]}}